|
| | Issue Date | Title | Contributor(s) | Type | Cat. |
| 81 | 2020 | One-Year Interim Analysis of Health-Related Quality of Life in RRMS Patients Treated With Alemtuzumab in a Real-world Clinical Setting (LemQoL Study) | VAN WIJMEERSCH, Bart; Harrower, T.; Hobart, J.; Kizlaitiene, R.; Marfia, G. A.; Patti, F.; Pearson, O. R.; Van Pesch, V.; Vanderdonckt, P.; Vecsei, L.; Shor, S.; Achiron, A. | Journal Contribution | M |
| 82 | 2020 | CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis | BOGIE, Jeroen; GRAJCHEN, Elien; WOUTERS, Elien; BROUX, Bieke; STINISSEN, Piet; VAN WIJMEERSCH, Bart; HENDRIKS, Jerome | Journal Contribution | A1 |
| 83 | 2020 | Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study | Ziemssen, Tjalf; Bass, Ann D.; Berkovich, Regina; Comi, Giancarlo; Eichau, Sara; Hobart, Jeremy; Hunter, Samuel F.; LaGanke, Christopher; Limmroth, Volker; Pelletier, Daniel; Pozzilli, Carlo; Schippling, Sven; Sousa, Livia; Traboulsee, Anthony; Uitdehaag, Bernard M. J.; VAN WIJMEERSCH, Bart; Choudhry, Zia; Daizadeh, Nadia; Singer, Barry A. | Journal Contribution | A1 |
| 84 | 2020 | The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective | Alroughani, Raed; VAN WIJMEERSCH, Bart; Al Khaboori, Jabber; Alsharoqi, Isa Ahmed; Ahmed, Samar F.; Hassan, Ali; Inshasi, Jihad; Krieger, Derk W.; Shakra, Mustafa; Shatila, Ahmed Osman; Szolics, Miklos; Khallaf, Mohamed; Ezzat, Aly | Journal Contribution | A1 |
| 85 | 2020 | Comparing 16 Different Dual–Tasking Paradigms in Individuals With Multiple Sclerosis and Healthy Controls: Working Memory Tasks Indicate Cognitive-Motor Interference | LEONE, Carmela; MOUMDJIAN, Lousin; Patti, Francesco; VANZEIR, Ellen; BAERT, Ilse; VELDKAMP, Renee; VAN WIJMEERSCH, Bart; FEYS, Peter | Journal Contribution | A1 |
| 86 | 2020 | Disability accrual in primary-progressive & secondary-progressive multiple sclerosis | Harding-Forrester, S.; Roos, I.; Sharmin, S; Diouf, I.; Malpas, C.; Nguyen, A. -L.; Moradi, N.; Horakova, D.; Havrdova, E. Kubala; Patti, F.; Izquierdo, G.; Eichau, S.; Prat, A.; Girard, M.; Duquette, P.; Onofrj, M.; Lugaresi, A.; Grand'Maison, F.; Weinstock-Guttman, B.; Amato, M. P.; Grammond, P.; Gerlach, O.; Ozakbas, S.; Sola, P.; Ferraro, D.; Butzkueven, H.; Lechner-Scott, J.; Boz, C.; Alroughani, R.; Van Pesch, V.; Cartechini, E.; Terzi, M.; Maimone, D.; Ramo-Tello, C.; Spitaleri, D.; Kappos, L.; Yamout, B.; Sa, M.; Slee, M.; Blanco, Y.; Bergamaschi, R.; Butler, E.; Iuliano, G.; Granella, F.; Sidhom, Y.; Gouider, R.; Ampapa, R.; VAN WIJMEERSCH, Bart; Karabudak, R.; Prevost, J.; Sanchez-Menoyo, J. L.; Verheul, F.; Mccombe, P.; Castillo-Trivino, T.; Macdonell, R.; Altintas, A.; Laureys, G.; Van Hijfte, L.; Van der Walt, A.; Vucic, S.; Turkoglu, R.; Barnett, M.; Cristiano, E.; Zakaria, M.; Shaygannejad, V.; Hodgkinson, S.; Soysal, A.; Kalincik, T. | Journal Contribution | M |
| 87 | 2020 | Ocrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmts | Wiendl, H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wuerfel, J.; Buffels, R.; Kadner, K.; Kuenzel, T.; Vermersch, P. | Journal Contribution | M |
| 88 | 2020 | Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab | Wiendl, Heinz; Carraro, Matthew; Comi, Giancarlo; Izquierdo, Guillermo; Kim, Ho Jin; Sharrack, Basil; Tornatore, Carlo; Daizadeh, Nadia; Chung, Luke; Jacobs, Alan K.; Hogan, Richard J.; Wychowski, Linda V.; VAN WIJMEERSCH, Bart | Journal Contribution | A1 |
| 89 | 2020 | Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) | Hartung, H-P; Comi, G.; Arnold, D. L.; Boyko, A. N.; Havrdova, E. K.; Inshasi, J. S.; McCombe, P.; Nakamura, K.; Oreja-Guevara, C.; Pelletier, D.; Pozzilli, C.; Selmaj, K. W.; Scott, T. F.; Chung, L.; Daizadeh, N.; Afsar, S.; VAN WIJMEERSCH, Bart | Journal Contribution | M |
| 90 | 2020 | Machine learning analysis of motor evoked potential time series to predict disability progression in multiple sclerosis | YPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; POPESCU, Veronica; HELLINGS, Niels; VAN WIJMEERSCH, Bart; PEETERS, Liesbet | Journal Contribution | A1 |
| 91 | 2020 | Deciphering the Morphology of Motor Evoked Potentials | YPERMAN, Jan; BECKER, Thijs; VALKENBORG, Dirk; HELLINGS, Niels; Cambron, M; Dive, D; Laureys, G.; POPESCU, Veronica; VAN WIJMEERSCH, Bart; PEETERS, Liesbet | Journal Contribution | A1 |
| 92 | 2019 | Effects of an individual 12-week communitylocated “start-to-run” program on physical capacity, walking, fatigue, cognitive function, brain volumes, and structures in persons with multiple sclerosis | Lousin Moumdjian; FEYS, Peter; Paul van Asch; Veronica Popescu; Bart Van Wijmeersch; Bert Opt' Eijnde; Inez Wens; Florian Van Haleweyck; Peter Feys; MOUMDJIAN, Lousin; VAN HALEWYCK, Florian; WENS, Inez; OP 'T EIJNDE, Bert; VAN WIJMEERSCH, Bart; POPESCU, Veronica; VAN ASCH, Paul | Journal Contribution | A1 |
| 93 | 2019 | A pilot study of the effects of running training on visuospatial memory in MS: A stronger functional embedding of the hippocampus in the default-mode network? | Huiskamp, Marijn; MOUMDJIAN, Lousin; VAN ASCH, Paul; POPESCU, Veronica; Schoonheim, Menno Michiel; Steenwijk, Martijn D.; VANZEIR, Ellen; VAN WIJMEERSCH, Bart; Geurts, Jeroen J. G.; FEYS, Peter; Hulst, Hanneke E. | Journal Contribution | A1 |
| 94 | 2019 | Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results) | Vermersch, P.; Eralinna, J. -P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuhelj, R.; Wei, W.; Comi, G. | Journal Contribution | M |
| 95 | 2019 | Phenotypic and Ig Repertoire Analyses Indicate a Common Origin of IgD-CD27- Double Negative B Cells in Healthy Individuals and Multiple Sclerosis Patients | FRAUSSEN, Judith; Marquez, Susanna; Takata, Kazushiro; BECKERS, Lien; MONTES DIAZ, Gwendoline; Zografou, Chrysoula; VAN WIJMEERSCH, Bart; Villar, Luisa M.; O'Connor, Kevin C.; Kleinstein, Steven H.; SOMERS, Veerle | Journal Contribution | A1 |
| 96 | 2019 | Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis | SHARMIN, Sohely; Lefort, M.; Andersen, J.; Horakova, D.; Havrdova, E. K.; Alroughani, R.; Izquierdo, G.; Eichau, S.; Ozakbas, S.; Butzkueven, H.; Patti, F.; Onofrj, M.; Lugaresi, A.; Terzi, M.; Grammond, P.; Grand'Maison, F.; Yamout, B.; Prat, A.; Girard, M.; Duquette, P.; Boz, C.; Trojano, M.; McCombe, P.; Slee, M.; Lechner-Scott, J.; Turkoglu, R.; Sola, P.; Ferraro, D.; Granella, F.; Shaygannejad, V.; Prevost, J.; Skibina, O.; Solaro, C.; Karabudak, R.; VAN WIJMEERSCH, Bart; Csepany, T.; Spitaleri, D.; Vucic, S.; Leray, E.; Sorensen, P. S.; Sellebjerg, F.; Magyari, M.; Vukusic, S.; Kalincik, T. | Journal Contribution | M |
| 97 | 2019 | Predicting long-term sustained disability progression in multiple sclerosis | SHARMIN, Sohely; Malpas, C.; Horakova, D.; Havrdova, E. K.; Izquierdo, G.; Eichau, S.; Trojano, M.; Prat, A.; Girard, M.; Duquette, P.; Onofrj, M.; Lugaresi, A.; Grand'Maison, F.; Grammond, P.; Sola, P.; Ferraro, D.; Terzi, M.; Hupperts, R.; Alroughani, R.; Boz, C.; Shaygannejad, V.; Van Pesch, V.; Cartechini, E.; Kappos, L.; Lechner-Scott, J.; Bergamaschi, R.; Turkoglu, R.; Solaro, C.; Ramo-Tello, C.; Iuliano, G.; Granella, F.; VAN WIJMEERSCH, Bart; Spitaleri, D.; Bolanos, R. F.; Slee, M.; McCombe, P.; Prevost, J.; Ampapa, R.; Ozakbas, S.; Sanchez-Menoyo, J. L.; Soysal, A.; Vucic, S.; Petersen, T.; Verheul, F.; Butler, E.; Hodgkinson, S.; Sidhom, Y.; Gouider, R.; Butzkueven, H.; Kalincik, T. | Journal Contribution | M |
| 98 | 2019 | Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings | Barclay, Krista; Carruthers, Robert; Traboulsee, Anthony; Bass, Ann D.; LaGanke, Christopher; Bertolotto, Antonio; Boster, Aaron; Celius, Elisabeth G.; de Seze, Jerome; Dela Cruz, Dionisio; Habek, Mario; Lee, Jong-Mi; Limmroth, Volker; Meuth, Sven G.; Oreja-Guevara, Celia; Pagnotta, Patricia; Vos, Cindy; Ziemssen, Tjalf; Baker, Darren P.; VAN WIJMEERSCH, Bart | Journal Contribution | A1 |
| 99 | 2019 | Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies | VAN WIJMEERSCH, Bart; Buffels, R.; Clinch, S.; Kuhelj, R.; Wei, W.; Vermersch, P. | Journal Contribution | M |
| 100 | 2019 | Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting | VAN WIJMEERSCH, Bart; Patti, F.; Hobart, J.; Kizlaitiene, R.; Vanderdonckt, P.; Shor, S.; Andreasen, A. K.; Uitdehaag, B. M. | Journal Contribution | M |
Loading...
5
0
5
0
false